Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 26, 2018

Generation and Analysis of Human T Cell Lines Responsive to Glatiramer Acetate (P5.363)

Peter Lipsky, Jeffrey Smith, Benjamin A. Tjoa, Anne Lodge
First published April 9, 2018,
Peter Lipsky
1AMPEL BioSolutions Charlottesville VA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Smith
2Mylan Laboratories Morgantown WV United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin A. Tjoa
3Astarte Biologics, Inc. Bothell WA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Lodge
3Astarte Biologics, Inc. Bothell WA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Generation and Analysis of Human T Cell Lines Responsive to Glatiramer Acetate (P5.363)
Peter Lipsky, Jeffrey Smith, Benjamin A. Tjoa, Anne Lodge
Neurology Apr 2018, 90 (15 Supplement) P5.363;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To establish a battery of human T cell lines with overall specificity for glatiramer acetate (GA), but differing in fine specificity and function, to test the immunologic bioequivalence of different preparations of GA.

Background: GA is indicated for the treatment of relapsing forms of multiple sclerosis. GA is a complex peptide composed of the amino acids YEAK, with many potential immunologic epitopes.

Design/Methods: A battery of GA-specific human T cell lines was generated from GA-naive human peripheral blood mononuclear cells via repetitive stimulation with either Copaxone® (COP) or generic Mylan GA (MGA), along with autologous antigen-presenting cells and expansion in the presence of interleukin-2. GA specificity of each T cell line was documented and the major histocompatibility complex (MHC) restriction of each line, responsiveness to altered peptide ligands, and cytokine secretory profiles were established. The reactivity of stable T cell lines was examined using multiple doses of COP and MGA to stimulate responsiveness in vitro.

Results: More than 30 GA-specific human T cell lines were generated from 3 donors. These lines exhibited different requirements for MHC Class II restricting elements, different fine specificities to di- and tri-peptides, and different responsiveness to YEAK peptides, with altered ratios of amino acids relative to GA. Additionally, individual T cell lines secreted varied cytokine profiles. Despite these differences, all T cell lines responded to multiple lots of COP and MGA comparably.

Conclusions: These results show that MGA and COP are recognized similarly by GA-specific human T cell lines, despite differences in the stimulating antigen used to generate the T cell lines, as well as the unique pattern of responsiveness of the lines. The identified GA-specific T cell lines show promise for use in a panel to compare the antigenic similarity of test and reference preparations of GA.

Disclosure: Dr. Lipsky has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Janssen, EMD Serono, Horizon, Sanofi, Roche, WSG&R. Dr. Smith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee: Mylan Inc. Dr. Tjoa has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employment at Astarte Biologics, Inc. Dr. Lodge has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employment at Astarte Biologics, Inc. Dr. Lodge holds stock and/or stock options in I am sole owner of Astarte Biologics, and we do fund internal research. Our internal research is strictly for the development of research products and services., which sponsored research in which Dr. Lodge was involved as an investigator.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise